BACKGROUND AND PURPOSE: For antibody therapies against receptor targets, in vivo outcomes can be difficult to predict because of target-mediated clearance or antigen 'sink' effects. The purpose of this work was to engineer an antibody to the GM-CSF receptor α (GM-CSFRα) with pharmacological properties optimized for chronic, s.c. treatment of rheumatoid arthritis (RA) patients. EXPERIMENTAL APPROACH: We used an in silico model of receptor occupancy to guide the target affinity and a combinatorial phage display approach for affinity maturation. Mechanism of action and internalization assays were performed on the optimized antibody in vitro before refining the modelling predictions of the eventual dosing in man. Finally, in vivo pharmacology studies in cynomolgus monkeys were carried out to inform the predictions and support future clinical development. KEY RESULTS: Antibody potency was improved 8600-fold, and the target affinity was reached. The refined model predicted pharmacodynamic effects at doses as low as 1 mg kg(-1) and a study in cynomolgus monkeys confirmed in vivo efficacy at 1 mg kg(-1) dosing. CONCLUSIONS AND IMPLICATIONS: This rational approach to antibody drug discovery enabled the isolation of a potent molecule compatible with chronic, s.c. self-administration by RA patients. We believe this general approach enables the development of optimal biopharmaceuticals.
BACKGROUND AND PURPOSE: For antibody therapies against receptor targets, in vivo outcomes can be difficult to predict because of target-mediated clearance or antigen 'sink' effects. The purpose of this work was to engineer an antibody to the GM-CSF receptor α (GM-CSFRα) with pharmacological properties optimized for chronic, s.c. treatment of rheumatoid arthritis (RA) patients. EXPERIMENTAL APPROACH: We used an in silico model of receptor occupancy to guide the target affinity and a combinatorial phage display approach for affinity maturation. Mechanism of action and internalization assays were performed on the optimized antibody in vitro before refining the modelling predictions of the eventual dosing in man. Finally, in vivo pharmacology studies in cynomolgus monkeys were carried out to inform the predictions and support future clinical development. KEY RESULTS: Antibody potency was improved 8600-fold, and the target affinity was reached. The refined model predicted pharmacodynamic effects at doses as low as 1 mg kg(-1) and a study in cynomolgus monkeys confirmed in vivo efficacy at 1 mg kg(-1) dosing. CONCLUSIONS AND IMPLICATIONS: This rational approach to antibody drug discovery enabled the isolation of a potent molecule compatible with chronic, s.c. self-administration by RApatients. We believe this general approach enables the development of optimal biopharmaceuticals.
Authors: C Plater-Zyberk; L A B Joosten; M M A Helsen; J Hepp; P A Baeuerle; W B van den Berg Journal: Ann Rheum Dis Date: 2006-10-04 Impact factor: 19.103
Authors: Ted R Mikuls; Brian T Fay; Kaleb Michaud; Harlan Sayles; Geoffrey M Thiele; Liron Caplan; Dannette Johnson; John S Richards; Gail S Kerr; Grant W Cannon; Andreas Reimold Journal: Rheumatology (Oxford) Date: 2010-07-21 Impact factor: 7.580
Authors: L Ottonello; M Cutolo; G Frumento; N Arduino; M Bertolotto; M Mancini; E Sottofattori; F Dallegri Journal: Rheumatology (Oxford) Date: 2002-11 Impact factor: 7.580
Authors: Jasvinder A Singh; Robin Christensen; George A Wells; Maria E Suarez-Almazor; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Elizabeth Tanjong Ghogomu; Peter Tugwell Journal: Cochrane Database Syst Rev Date: 2009-10-07
Authors: Gerd R Burmester; Eugen Feist; Matthew A Sleeman; Bing Wang; Barbara White; Fabio Magrini Journal: Ann Rheum Dis Date: 2011-05-25 Impact factor: 19.103
Authors: Frank R Brennan; Joy Cavagnaro; Kathleen McKeever; Patricia C Ryan; Melissa M Schutten; John Vahle; Gerhard F Weinbauer; Estelle Marrer-Berger; Lauren E Black Journal: MAbs Date: 2017-10-26 Impact factor: 5.857
Authors: Michael E Weinblatt; Iain B McInnes; Joel M Kremer; Pedro Miranda; Jiri Vencovsky; Xiang Guo; Wendy I White; Patricia C Ryan; Alex Godwood; Marius Albulescu; David Close; Gerd R Burmester Journal: Arthritis Rheumatol Date: 2018-01 Impact factor: 10.995
Authors: E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May Journal: MAbs Date: 2014-02-28 Impact factor: 5.857
Authors: D E A Greven; E S Cohen; D M Gerlag; J Campbell; J Woods; N Davis; A van Nieuwenhuijze; A Lewis; S Heasmen; M McCourt; D Corkill; A Dodd; J Elvin; G Statache; I P Wicks; I K Anderson; A Nash; M A Sleeman; P P Tak Journal: Ann Rheum Dis Date: 2014-06-16 Impact factor: 19.103
Authors: Dirk Woetzel; Rene Huber; Peter Kupfer; Dirk Pohlers; Michael Pfaff; Dominik Driesch; Thomas Häupl; Dirk Koczan; Peter Stiehl; Reinhard Guthke; Raimund W Kinne Journal: Arthritis Res Ther Date: 2014-04-01 Impact factor: 5.156
Authors: Con Panousis; Urmi Dhagat; Kirsten M Edwards; Veronika Rayzman; Matthew P Hardy; Hal Braley; Gail M Gauvreau; Timothy R Hercus; Steven Smith; Roma Sehmi; Laura McMillan; Mara Dottore; Barbara J McClure; Louis J Fabri; Gino Vairo; Angel F Lopez; Michael W Parker; Andrew D Nash; Nicholas J Wilson; Michael J Wilson; Catherine M Owczarek Journal: MAbs Date: 2015-12-14 Impact factor: 5.857
Authors: Julie A Douthwaite; Sudharsan Sridharan; Catherine Huntington; Jayne Hammersley; Rose Marwood; Jonna K Hakulinen; Margareta Ek; Tove Sjögren; David Rider; Cyril Privezentzev; Jonathan C Seaman; Peter Cariuk; Vikki Knights; Joyce Young; Trevor Wilkinson; Matthew Sleeman; Donna K Finch; David C Lowe; Tristan J Vaughan Journal: MAbs Date: 2015 Impact factor: 5.857